EndoChoice To Present At J.P. Morgan Healthcare Conference
ATLANTA, Dec. 18, 2013 /PRNewswire/ -- EndoChoice announced today it will present at the 32 nd annual J.P. Morgan Healthcare Conference. Mark Gilreath, Founder and CEO at EndoChoice will review the company's future prospects while summarizing five consecutive years of quarterly revenue growth.
Mr. Gilreath will be presenting on Wednesday, January 15, 2014 at 930am in the Elizabethan C meeting room at the Westin St. Francis Hotel in San Francisco. The conference will take place Monday, January 13, through Thursday, January 16, 2014.
The annual J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry. The expected attendance includes more than 300 companies, both public and private, to deliver presentations to more than 3,000 investors.
About EndoChoiceBased in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com.For more information, press only: Doug Ladd, Chief Marketing Officer513-608-6873 or Doug.Ladd@endochoice.com For more information on EndoChoice® www.endochoice.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts